Optimizing Use of ‘Big Data’ for Patient Identification and Disease Management

Co-Chairs: Larry Alphs, MD, PhD;  Gayle Wittenberg, PhD

‘Big data’ has become a buzz word referring to extremely large data sets that can be analyzed to reveal patterns, trends, and relationships among data elements. Despite the overuse of the term, the value that big data can bring to public health questions, its limitations and how to harness its use for clinical trial design, regulatory and public policy use remain incompletely addressed.  This day-long session will focus on 1) different sources of big data and the questions they address; 2) challenges involved in aggregating and analyzing these data; 3) how their value can be harnessed to impact CNS clinical trials; 4) identifying and outlining current gaps towards use in regulatory, payer, and public health settings.